PC
RYTM icon

PointState Capital’s Rhythm Pharmaceuticals RYTM Stock Holding History

PointState Capital’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-85,000
Closed -$2.66M – 176
2018
Q2 		$2.66M Buy
+85,000
New +$2.32M 0.03% 133

Other funds holding RYTM

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
TG
TRV GP Boston, Massachusetts $18.9M AUM 541.67% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

PointState Capital's RYTM Position: Q3 2018 in Review

PointState Capital sold out of Rhythm Pharmaceuticals (RYTM) in Q3 2018, closing a stake of 85,000 shares — an estimated $2.66M sold.

PointState Capital first reported a position in RYTM in Q2 2018 and held it in 1 quarter. The position peaked at $2.66M in Q2 2018. 78 funds tracked by Wall St. Rank hold RYTM as of Q3 2018.

  • PointState Capital reported no remaining Rhythm Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • PointState Capital sold 85,000 Rhythm Pharmaceuticals shares in Q3 2018, an estimated $2.66M.
  • PointState Capital first reported a position in Rhythm Pharmaceuticals in Q2 2018 and held it in 1 quarter.
  • PointState Capital's Rhythm Pharmaceuticals position peaked at $2.66M in Q2 2018.
  • 78 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q3 2018.

Based on PointState Capital's 13F filing for Q3 2018, filed 14 Nov 2018.